dc.contributor.author |
Bonnet A. |
dc.contributor.author |
Randrianarison-Huetz V. |
dc.contributor.author |
Nzounza P. |
dc.contributor.author |
Nedelec M. |
dc.contributor.author |
Chazal M. |
dc.contributor.author |
Waast L. |
dc.contributor.author |
Pene S. |
dc.contributor.author |
Bazarbachi A. |
dc.contributor.author |
Mahieux R. |
dc.contributor.author |
Benit L. |
dc.contributor.author |
Pique C. |
dc.contributor.editor |
|
dc.date |
2012 |
dc.date.accessioned |
2017-10-05T15:41:37Z |
dc.date.available |
2017-10-05T15:41:37Z |
dc.date.issued |
2012 |
dc.identifier |
10.1186/1742-4690-9-77 |
dc.identifier.isbn |
|
dc.identifier.issn |
17424690 |
dc.identifier.uri |
http://hdl.handle.net/10938/18098 |
dc.description.abstract |
Background: The Tax protein encoded by Human T-lymphotropic virus type 1 (HTLV-1) is a powerful activator of the NF-κB pathway, a property critical for HTLV-1-induced immortalization of CD4+ T lymphocytes. Tax permanently stimulates this pathway at a cytoplasmic level by activating the IκB kinase (IKK) complex and at a nuclear level by enhancing the binding of the NF-κB factor RelA to its cognate promoters and by forming nuclear bodies, believed to represent transcriptionally active structures. In previous studies, we reported that Tax ubiquitination and SUMOylation play a critical role in Tax localization and NF-κB activation. Indeed, analysis of lysine Tax mutants fused or not to ubiquitin or SUMO led us to propose a two-step model in which Tax ubiquitination first intervenes to activate IKK while Tax SUMOylation is subsequently required for promoter activation within Tax nuclear bodies. However, recent studies showing that ubiquitin or SUMO can modulate Tax activities in either the nucleus or the cytoplasm and that SUMOylated Tax can serve as substrate for ubiquitination suggested that Tax ubiquitination and SUMOylation may mediate redundant rather than successive functions.Results: In this study, we analyzed the properties of a new Tax mutant that is properly ubiquitinated, but defective for both nuclear body formation and SUMOylation. We report that reducing Tax SUMOylation and nuclear body formation do not alter the ability of Tax to activate IKK, induce RelA nuclear translocation, and trigger gene expression from a NF-κB promoter. Importantly, potent NF-κB promoter activation by Tax despite low SUMOylation and nuclear body formation is also observed in T cells, including CD4+ primary T lymphocytes. Moreover, we show that Tax nuclear bodies are hardly observed in HTLV-1-infected T cells. Finally, we provide direct evidence that the degree of NF-κB activation by Tax correlates with the level of Tax ubiquitination, but not SUMOylation.Conclusions: These data reveal that the formation of Tax nuclear bodies, previously associated to transcriptional activities in Tax-transfected cells, is dispensable for NF-κB promoter activation, notably in CD4+ T cells. They also provide the first evidence that Tax SUMOylation is not a key determinant for Tax-induced NF-κB activation. © 2012 Bonnet et al.; licensee BioMed Central Ltd. |
dc.format.extent |
|
dc.language |
English |
dc.publisher |
LONDON |
dc.relation.ispartof |
Publication Name: Retrovirology; Publication Year: 2012; Volume: 9; |
dc.relation.ispartofseries |
|
dc.relation.uri |
|
dc.source |
Scopus |
dc.subject.other |
|
dc.title |
Low nuclear body formation and tax SUMOylation do not prevent NF-kappaB promoter activation |
dc.type |
Article |
dc.contributor.affiliation |
Bonnet, A., INSERM, U1016, Institut Cochin, 22 rue Méchain, 75014 Paris, France, CNRS, UMR8104, Paris, France, Université Paris Descartes, Sorbonne Paris Cité, Paris, France |
dc.contributor.affiliation |
Randrianarison-Huetz, V., INSERM, U1016, Institut Cochin, 22 rue Méchain, 75014 Paris, France, CNRS, UMR8104, Paris, France, Université Paris Descartes, Sorbonne Paris Cité, Paris, France |
dc.contributor.affiliation |
Nzounza, P., INSERM, U1016, Institut Cochin, 22 rue Méchain, 75014 Paris, France, CNRS, UMR8104, Paris, France, Université Paris Descartes, Sorbonne Paris Cité, Paris, France |
dc.contributor.affiliation |
Nedelec, M., INSERM, U1016, Institut Cochin, 22 rue Méchain, 75014 Paris, France, CNRS, UMR8104, Paris, France, Université Paris Descartes, Sorbonne Paris Cité, Paris, France |
dc.contributor.affiliation |
Chazal, M., INSERM, U1016, Institut Cochin, 22 rue Méchain, 75014 Paris, France, CNRS, UMR8104, Paris, France, Université Paris Descartes, Sorbonne Paris Cité, Paris, France |
dc.contributor.affiliation |
Waast, L., INSERM, U1016, Institut Cochin, 22 rue Méchain, 75014 Paris, France, CNRS, UMR8104, Paris, France, Université Paris Descartes, Sorbonne Paris Cité, Paris, France |
dc.contributor.affiliation |
Pene, S., INSERM, U1016, Institut Cochin, 22 rue Méchain, 75014 Paris, France, CNRS, UMR8104, Paris, France, Université Paris Descartes, Sorbonne Paris Cité, Paris, France |
dc.contributor.affiliation |
Bazarbachi, A., Department of Internal Medicine, American University of Beirut, Beirut, Lebanon |
dc.contributor.affiliation |
Mahieux, R., INSERM, U758, Ecole Normale Supérieure de Lyon, Lyon, France |
dc.contributor.affiliation |
Bénit, L., INSERM, U1016, Institut Cochin, 22 rue Méchain, 75014 Paris, France, CNRS, UMR8104, Paris, France, Université Paris Descartes, Sorbonne Paris Cité, Paris, France |
dc.contributor.affiliation |
Pique, C., INSERM, U1016, Institut Cochin, 22 rue Méchain, 75014 Paris, France, CNRS, UMR8104, Paris, France, Université Paris Descartes, Sorbonne Paris Cité, Paris, France |
dc.contributor.authorAddress |
Pique, C.; INSERM, U1016, Institut Cochin, 22 rue Méchain, 75014 Paris, France; email: claudine.pique@inserm.fr |
dc.contributor.authorCorporate |
University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; |
dc.contributor.authorDepartment |
Internal Medicine |
dc.contributor.authorDivision |
|
dc.contributor.authorEmail |
claudine.pique@inserm.fr |
dc.contributor.faculty |
Faculty of Medicine |
dc.contributor.authorInitials |
Bonnet, A |
dc.contributor.authorInitials |
Randrianarison-Huetz, V |
dc.contributor.authorInitials |
Nzounza, P |
dc.contributor.authorInitials |
Nedelec, M |
dc.contributor.authorInitials |
Chazal, M |
dc.contributor.authorInitials |
Waast, L |
dc.contributor.authorInitials |
Pene, S |
dc.contributor.authorInitials |
Bazarbachi, A |
dc.contributor.authorInitials |
Mahieux, R |
dc.contributor.authorInitials |
Benit, L |
dc.contributor.authorInitials |
Pique, C |
dc.contributor.authorOrcidID |
|
dc.contributor.authorReprintAddress |
Pique, C (reprint author), INSERM, U1016, Inst Cochin, 22 Rue Mechain, F-75014 Paris, France. |
dc.contributor.authorResearcherID |
|
dc.contributor.authorUniversity |
American University of Beirut Medical Center |
dc.description.cited |
Au Ping-Yee Billie, 2007, Adv Exp Med Biol, V597, P32; Baydoun H, 2007, GENE, V386, P191, DOI 10.1016-j.gene.2006.09.008; Bex F, 1997, J VIROL, V71, P3484; BHAT NK, 1993, VIROLOGY, V196, P15, DOI 10.1006-viro.1993.1450; Boxus M, 2008, RETROVIROLOGY, V5, DOI 10.1186-1742-4690-5-76; Chiari E, 2004, J VIROL, V78, P11823, DOI 10.1128-JVI.78.21.11823-11832.2004; Chin KT, 2007, CANCER RES, V67, P1072, DOI 10.1158-0008-5472.CAN-06-3053; Durkin SS, 2008, J BIOL CHEM, V283, P36311, DOI 10.1074-jbc.M804931200; Fryrear KA, 2012, BLOOD, V119, P1173, DOI 10.1182-blood-2011-06-358564; Fryrear KA, 2009, J VIROL, V83, P5339, DOI 10.1128-JVI.00232-09; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083-jcb.146.6.1239; Gatza ML, 2007, RETROVIROLOGY, V4, DOI 10.1186-1742-4690-4-95; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074-jbc.274.33.22911; Harhaj NS, 2007, J BIOL CHEM, V282, P4185, DOI 10.1074-jbc.M611031200; Journo C, 2009, PLOS PATHOG, V5, DOI 10.1371-journal.ppat.1000521; Journo C, 2009, FUTURE MICROBIOL, V4, P425, DOI [10.2217-fmb.09.13, 10.2217-FMB.09.13]; Kfoury Y, 2008, ONCOGENE, V27, P1665, DOI 10.1038-sj.onc.1210804; Kfoury Y, 2011, BLOOD, V117, P190, DOI 10.1182-blood-2010-05-285742; Lamsoul I, 2005, MOL CELL BIOL, V25, P10391, DOI 10.1128-MCB.25.23.10391-10406.2005; Lavorgna A, 2012, J VIROL, V86, P3357, DOI 10.1128-JVI.06456-11; Lodewick J, 2011, VIRUSES-BASEL, V3, P829, DOI 10.3390-v3060829; Nasr R, 2006, BLOOD, V107, P4021, DOI 10.1182-blood-2005-09-3572; Peloponese JM, 2004, J VIROL, V78, P11686, DOI 10.1128-JVI.78.21.11686-11695.2004; Peloponese JM, 2007, INT J HEMATOL, V86, P101, DOI 10.1532-IJH97.07087; Petropoulos L, 1996, VIROLOGY, V225, P52, DOI 10.1006-viro.1996.0574; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073-pnas.77.12.7415; Robek MD, 1999, J VIROL, V73, P4856; Semmes OJ, 1996, J VIROL, V70, P6347; Shembade N, 2010, SCIENCE, V327, P1135, DOI 10.1126-science.1182364; Shembade N, 2008, NAT IMMUNOL, V9, P254, DOI 10.1038-ni1563; Shembade N, 2007, J VIROL, V81, P13735, DOI 10.1128-JVI.01790-07; Shibata Y, 2011, J BIOCHEM, V150, P679, DOI 10.1093-jb-mvr106; Sun SC, 2005, ONCOGENE, V24, P5952, DOI 10.1038-sj.onc.1208969; Sun Y, 2003, CANCER BIOL THER, V2, P623; SUZUKI T, 1994, ONCOGENE, V9, P3099; Taylor JM, 2008, APOPTOSIS, V13, P733, DOI 10.1007-s10495-008-0208-7; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146-annurev.immunol.021908.132641; Wang YT, 2011, J MOL BIOL, V414, P1, DOI 10.1016-j.jmb.2011.09.027; Yasunaga J, 2011, J VIROL, V85, P6212, DOI 10.1128-JVI.00079-11; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016-S1097-2765(00)80334-2; Yu QS, 2008, BIOCHEM BIOPH RES CO, V365, P189, DOI 10.1016-j.bbrc.2007.10.172 |
dc.description.citedCount |
10 |
dc.description.citedTotWOSCount |
11 |
dc.description.citedWOSCount |
11 |
dc.format.extentCount |
1 |
dc.identifier.articleNo |
77 |
dc.identifier.coden |
|
dc.identifier.pubmedID |
23009398 |
dc.identifier.scopusID |
84866538111 |
dc.identifier.url |
|
dc.publisher.address |
236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND |
dc.relation.ispartofConference |
|
dc.relation.ispartofConferenceCode |
|
dc.relation.ispartofConferenceDate |
|
dc.relation.ispartofConferenceHosting |
|
dc.relation.ispartofConferenceLoc |
|
dc.relation.ispartofConferenceSponsor |
|
dc.relation.ispartofConferenceTitle |
|
dc.relation.ispartofFundingAgency |
|
dc.relation.ispartOfISOAbbr |
Retrovirology |
dc.relation.ispartOfIssue |
|
dc.relation.ispartOfPart |
|
dc.relation.ispartofPubTitle |
Retrovirology |
dc.relation.ispartofPubTitleAbbr |
Retrovirology |
dc.relation.ispartOfSpecialIssue |
|
dc.relation.ispartOfSuppl |
|
dc.relation.ispartOfVolume |
9 |
dc.source.ID |
WOS:000310008700001 |
dc.type.publication |
Journal |
dc.subject.otherAuthKeyword |
Leukemia |
dc.subject.otherAuthKeyword |
NF-kappaB |
dc.subject.otherAuthKeyword |
Nuclear speckles |
dc.subject.otherAuthKeyword |
Retrovirus |
dc.subject.otherAuthKeyword |
SUMO |
dc.subject.otherAuthKeyword |
Ubiquitin |
dc.subject.otherChemCAS |
I kappa B kinase, 209902-66-9 |
dc.subject.otherChemCAS |
CREB1 protein, human |
dc.subject.otherChemCAS |
Cyclic AMP Response Element-Binding Protein |
dc.subject.otherChemCAS |
Gene Products, tax |
dc.subject.otherChemCAS |
I-kappa B Kinase, 2.7.11.10 |
dc.subject.otherChemCAS |
IKBKG protein, human |
dc.subject.otherChemCAS |
Luciferases, Renilla, 1.13.12.5 |
dc.subject.otherChemCAS |
NF-kappa B |
dc.subject.otherChemCAS |
Recombinant Fusion Proteins |
dc.subject.otherChemCAS |
SUMO-1 Protein |
dc.subject.otherChemCAS |
tax protein, Human T-lymphotrophic virus 1 |
dc.subject.otherIndex |
I kappa B kinase |
dc.subject.otherIndex |
immunoglobulin enhancer binding protein |
dc.subject.otherIndex |
Tax protein |
dc.subject.otherIndex |
transcription factor RelA |
dc.subject.otherIndex |
article |
dc.subject.otherIndex |
CD4+ T lymphocyte |
dc.subject.otherIndex |
cell nucleus |
dc.subject.otherIndex |
cell nucleus inclusion body |
dc.subject.otherIndex |
controlled study |
dc.subject.otherIndex |
cytoplasm |
dc.subject.otherIndex |
gene expression |
dc.subject.otherIndex |
human |
dc.subject.otherIndex |
human cell |
dc.subject.otherIndex |
Human T cell leukemia virus 1 |
dc.subject.otherIndex |
nonhuman |
dc.subject.otherIndex |
promoter region |
dc.subject.otherIndex |
sumoylation |
dc.subject.otherIndex |
ubiquitination |
dc.subject.otherIndex |
Amino Acid Substitution |
dc.subject.otherIndex |
CD4-Positive T-Lymphocytes |
dc.subject.otherIndex |
Cell Line |
dc.subject.otherIndex |
Cyclic AMP Response Element-Binding Protein |
dc.subject.otherIndex |
Gene Products, tax |
dc.subject.otherIndex |
Genes, Reporter |
dc.subject.otherIndex |
Host-Pathogen Interactions |
dc.subject.otherIndex |
Human T-lymphotropic virus 1 |
dc.subject.otherIndex |
Humans |
dc.subject.otherIndex |
I-kappa B Kinase |
dc.subject.otherIndex |
Intranuclear Space |
dc.subject.otherIndex |
Luciferases, Renilla |
dc.subject.otherIndex |
Microscopy, Confocal |
dc.subject.otherIndex |
NF-kappa B |
dc.subject.otherIndex |
Promoter Regions, Genetic |
dc.subject.otherIndex |
Protein Binding |
dc.subject.otherIndex |
Protein Processing, Post-Translational |
dc.subject.otherIndex |
Protein Transport |
dc.subject.otherIndex |
Recombinant Fusion Proteins |
dc.subject.otherIndex |
Signal Transduction |
dc.subject.otherIndex |
SUMO-1 Protein |
dc.subject.otherIndex |
Sumoylation |
dc.subject.otherIndex |
Transcription, Genetic |
dc.subject.otherIndex |
Transcriptional Activation |
dc.subject.otherIndex |
Ubiquitination |
dc.subject.otherIndex |
Human T-lymphotropic virus 1 |
dc.subject.otherKeywordPlus |
VIRUS TYPE-1 TAX |
dc.subject.otherKeywordPlus |
B ACTIVATION |
dc.subject.otherKeywordPlus |
CELLULAR-TRANSFORMATION |
dc.subject.otherKeywordPlus |
GENE-EXPRESSION |
dc.subject.otherKeywordPlus |
ONCOPROTEIN TAX |
dc.subject.otherKeywordPlus |
HTLV-I |
dc.subject.otherKeywordPlus |
PROTEIN |
dc.subject.otherKeywordPlus |
UBIQUITINATION |
dc.subject.otherKeywordPlus |
TRANSCRIPTION |
dc.subject.otherKeywordPlus |
LOCALIZATION |
dc.subject.otherWOS |
Virology |